NICE Endorses Brilique at a Lower Dosage for Extended Treatment

The UK’s drug pricing watchdog is recommending reimbursement of AstraZeneca’s drug Brilique for patients with a previous history of heart attacks.

In draft guidance, the National Institute for Health and Care Excellence recommended that the drug be reimbursed at a lower dosage as a continuing treatment for patients who have suffered a heart attack within the past year and are at risk of further heart events.

Under the recommendation, patients would take 60 mg of Brilique in combination with aspirin twice daily.